EVR News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$9.77B

Volume

475.05K

Next Earnings

October 28th

Mkt Cap

$9.77B

Volume

475.05K

Next Earnings

October 28th

Chart Financials Earnings News About Dividends Insider Filings

Bear of the Day: Evercore (EVR)Evercore (EVR) has been downgraded to a Zacks Rank #5 (Strong Sell) as earnings estimates decline sharply and the stock falls 25% year-to-date. FY26 and FY27 EPS estimates have dropped 7% and 6% respectively, while Q3 estimates plunged 23% in one week. Rising Treasury yields above 5.3% and higher interest rates threaten investment banking activity and dealmaking, pressuring the firm's advisory and underwriting revenue.Zacks Investment Research · Oct 15, 2026

Kinzey Capital Management: Electra Sets Nasdaq IPO TermsElectra Therapeutics is pricing 21.7 million shares at $14-$16 each on Nasdaq under ticker ETRA, targeting up to $347 million to advance ipsoprubart through its SURPASS registration trial for secondary haemophagocytic lymphohistiocytosis. The offering values the clinical-stage antibody developer near $1 billion, with frontline data showing 100% overall survival at eight weeks versus historical 20-30% mortality rates.GlobeNewswire Inc. · Sep 19, 2026

Houlihan Lokey Down 21% YTD: Buy the Dip or Stay Cautious?Houlihan Lokey (HLI) shares have declined 21.3% year-to-date due to two disappointing quarters, a 24% revenue drop in Corporate Finance, and a 54% decline in technology-related revenues. While the company maintains record backlog and a diversified business model, earnings estimates remain under pressure with a consensus decline of 8.3% expected. Analysts recommend avoiding the stock until operating trends stabilize.Zacks Investment Research · Sep 7, 2026

U.S. Treasury Secretary Scott Bessent's Plan to Calm the Bond Market Could Have Unintended Consequences for Fed Chair Kevin WarshTreasury Secretary Scott Bessent announced an expansion of the Treasury's bond repurchase program from $2 billion to at least $4 billion of longer-dated bonds to ease long-term yields. However, this move could undermine Fed Chair Kevin Warsh's hawkish stance on inflation control, potentially creating confusion about whether the Treasury or Fed is driving monetary policy. The expanded program may weaken the dollar and lead to higher inflation, while also making it difficult for Warsh to justify raising interest rates.The Motley Fool · Aug 26, 2026

Sandisk Stock Plunged Today. Analysts Say Buy the Dip.Sandisk shares dropped 12.54% on Monday amid a broader chip stock pullback. However, major Wall Street analysts remain bullish, with Goldman Sachs raising its price target to $2,200 and Evercore lifting its target to $3,100. Both analysts cite sustained AI-driven demand for memory chips from data center operators as justification for their optimistic outlooks.The Motley Fool · Jul 14, 2026

Hemab Therapeutics Announces Pricing of Upsized Initial Public OfferingHemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company focused on blood coagulation disorder treatments, priced its initial public offering at $18.00 per share for 16.75 million shares, raising approximately $301.5 million in gross proceeds. The company's stock is expected to begin trading on Nasdaq under ticker symbol 'COAG' on May 1, 2026, with the offering expected to close on May 4, 2026.GlobeNewswire Inc. · Apr 30, 2026

Evercore Rides M&A Momentum, Analyst Calls It 'Best Pure-Play Boutique Investment Bank'BofA Securities initiated coverage of Evercore (NYSE:EVR) with a Buy rating and $435 price target, calling it the 'best pure-play among boutique investment banks.' The analyst highlights Evercore's high advisory revenue mix (80% of total), strong M&A expertise, and growth potential from franchise expansion. With M&A activity expected to reach record highs in 2026, the firm is positioned for positive earnings revisions.Benzinga · Jan 26, 2026

ProQR to Participate in 8th Annual Evercore Healthcare ConferenceProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference, presenting its Axiomer™ RNA editing technology platform that enables targeted single nucleotide changes in RNA to potentially develop new disease treatments.GlobeNewswire Inc. · Dec 1, 2025

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor ConferencesMadrigal Pharmaceuticals will participate in three upcoming healthcare investor conferences in November and December 2025, presenting live webcasts about their MASH treatment Rezdiffra.GlobeNewswire Inc. · Nov 17, 2025

The Stock Market May Do Something Shocking in 2026, According to Wall Street AnalystsWall Street analysts predict the S&P 500 could experience significant volatility in 2026, with potential scenarios ranging from a 30% surge to a 30% decline, driven by factors like AI adoption, economic conditions, and potential interest rate changes.The Motley Fool · Oct 29, 2025

EVREvercore Inc.

EVR

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any EVR yet.

Related Tickers

Earnings

Dividends

Last · Aug 28Quarterly

Amount$0.89

Yield1.36%

Annual$3.46

Mkt Cap

$9.77B

Volume

475.05K

Next Earnings

October 28th